GLP-1 (9-36) amide: Antagonist Peptide for GLP-1 Receptor Pathway Studies

Executive Summary: GLP-1 (9-36) amide is a synthetic peptide antagonist targeting the human GLP-1 receptor (GLP-1R) (Chepurny et al., 2019). It is used to dissect GLP-1R signaling in metabolic regulation and type 2 diabetes research. The product is supplied by APExBIO with validated ≥99% purity, confirmed by HPLC and mass spectrometry (APExBIO Product Page). It is insoluble in DMSO, water, and ethanol, requiring specialized handling. Its antagonistic activity is pivotal for distinguishing GLP-1R-mediated effects from off-target GPCR signaling (Chepurny et al., 2019).

Biological Rationale

GLP-1 (9-36) amide is derived from the native incretin hormone GLP-1, which is secreted by enteroendocrine L-cells in response to nutrient intake (Chepurny et al., 2019). GLP-1 binds to the GLP-1 receptor (GLP-1R), a class B G protein–coupled receptor (GPCR) expressed on pancreatic β-cells, neurons, and other tissues. The GLP-1/GLP-1R axis is essential for glucose-dependent insulin secretion, appetite suppression, and systemic glucose homeostasis. GLP-1 (9-36) amide, a truncated, amide-modified peptide, functions as a specific antagonist at the human GLP-1R. This enables researchers to pinpoint receptor-mediated effects and isolate cAMP pathway responses in vitro and in vivo (Fig. 2, Chepurny et al., 2019).

Mechanism of Action of GLP-1 (9-36) amide

GLP-1 (9-36) amide competitively binds the orthosteric site of the GLP-1 receptor, blocking endogenous GLP-1 or synthetic agonist-induced receptor activation (Chepurny et al., 2019). By occupying the receptor site, it prevents conformational changes necessary for Gs protein coupling and downstream cAMP production. This inhibition can be quantified using FRET-based cAMP biosensor assays, such as those described in INS-1 832/13 pancreatic β-cell models. The antagonist activity is dose-dependent, effective at nanomolar to low micromolar concentrations under physiological buffer conditions (HEPES, pH 7.4, 25°C) (Fig. 3).

Evidence & Benchmarks

• GLP-1 (9-36) amide blocks GLP-1R-mediated cAMP accumulation in INS-1 832/13 cells at 100 nM, as measured by FRET-based biosensor, reducing cAMP levels by ≥80% compared to agonist control (Chepurny et al., 2019, DOI).
• The peptide shows negligible antagonism at glucagon or GIP receptors at concentrations up to 10 μM, confirming high selectivity (Chepurny et al., 2019, DOI).
• GLP-1 (9-36) amide is confirmed ≥99% pure by HPLC and mass spectrometry quality control (APExBIO Product Sheet, Product Page).
• Stability is ensured for ≥12 months when stored desiccated at -20°C; instability arises within 24 hours in solution at room temperature (APExBIO, Product Page).

Applications, Limits & Misconceptions

GLP-1 (9-36) amide is a reference antagonist for dissecting GLP-1R signaling in metabolic regulation, type 2 diabetes, and incretin hormone research. It is used for benchmarking new GLP-1R modulators and for distinguishing direct GLP-1R effects in cell-based and animal models. Comparable approaches are discussed in Chepurny et al., 2019, where dual and triagonist GPCR signaling is evaluated using selective antagonists.

For broader context, see our overview on GLP-1 agonist compounds, which details agonist activities and complements this article's antagonist focus. This article extends those findings by delineating direct receptor blockade strategies.

Common Pitfalls or Misconceptions

• GLP-1 (9-36) amide does not antagonize the glucagon or GIP receptor at relevant concentrations; it is not a pan-GPCR inhibitor (Chepurny et al., 2019).
• It is not soluble in water, DMSO, or ethanol; improper solvent use leads to precipitation and loss of activity (APExBIO Product Page).
• The peptide is unstable in solution; long-term storage of dissolved aliquots is not recommended.
• It should not be used as a therapeutic agent; for research use only (APExBIO).
• GLP-1 (9-36) amide does not reverse established GLP-1-dependent physiological changes once initiated.

Workflow Integration & Parameters

GLP-1 (9-36) amide is provided as a white lyophilized solid (molecular weight: 3089.44 Da; chemical formula: C140H214N36O43). It requires desiccated storage at -20°C and is shipped on blue ice. Each batch is supplied with a Certificate of Analysis and MSDS, confirming identity and purity (≥99%) by HPLC/mass spectrometry (APExBIO). Due to insolubility in common solvents, reconstitution protocols may involve specialized buffer systems or co-solvents. Use the peptide immediately after preparation; do not freeze-thaw dissolved aliquots. For in vitro assays, titrate from 1 nM to 10 μM depending on receptor expression and assay sensitivity (Chepurny et al., 2019).

The product (B5404) from APExBIO is suitable for cell-based cAMP production assays, receptor-binding studies, and as a negative control for GLP-1R-targeted drug screens. For reference, see the GLP-1 (9-36) amide product page for batch-specific documentation.

Conclusion & Outlook

GLP-1 (9-36) amide is a validated, high-purity antagonist peptide for selective interrogation of the GLP-1 receptor pathway. It is essential for metabolic and diabetes research requiring precise receptor deconvolution. Ongoing studies using FRET-cAMP biosensors and hybrid peptide screens are refining our understanding of GPCR signaling crosstalk (Chepurny et al., 2019). Future directions include triagonist development and combinatorial receptor modulation for metabolic disease therapy. For detailed protocols and QC information, consult APExBIO's resources and product documentation.